Correlation Engine 2.0
Clear Search sequence regions


  • antibodies (2)
  • blinatumomab (5)
  • free (1)
  • humans (1)
  • leukemia (7)
  • patients (1)
  • research (1)
  • t- cell (2)
  • therapies (2)
  • Sizes of these terms reflect their relevance to your search.

    Blinatumomab, a bispecific T-cell engager (BiTE) associated with improved survival in relapsed or refractory acute lymphoblastic leukemia (ALL), was recently approved for treatment of minimal residual disease (MRD). MRD is an important predictor of survival in ALL, and recent studies suggest that achievement of MRD-negativity with blinatumomab improves outcomes in patients with ALL. However, further research is needed to determine how to optimally incorporate blinatumomab, and other novel therapies, into current therapies for ALL. © 2019 by The American Society of Hematology.

    Citation

    Emily Curran, Wendy Stock. Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL. Blood. 2019 Apr 18;133(16):1715-1719

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 30796026

    View Full Text